49 GLP-1RAs represent a pharmacotherapeutic category of injectable hypoglycemic agents that are sanctioned as adjunctive therapies to diet and exercise for the management of type 2 diabetes mellitus (T2DM) in adult patients and potentially hold promise in addressing other medical conditions
Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an analysis of the placebo arm of EXSCEL
Receptors GLP-1 GLP-1 + GIP GLP-1 + GIP + Glucagon Class Single-agonist Dual-agonist Triple-agonist Generation First Second Third Brand Names Ozempic / Wegovy Mounjaro / Zepbound Not yet approved Phase 2 Weight Loss (peak) ~14.9% ~20.9% 24.2% Approval Status FDA approved FDA approved Phase 3 trials A common question: is the difference between 20.9% (tirzepatide) and 24.2% (retatrutide) really that significant
For example, if a patient is taking three medications for high blood pressure and successfully loses weight on Wegovy, she said there is a good chance that one, two, or even all three of the patients antihypertensives could be discontinued
The one clear fact was that patients with duodenal ulcers gave an exaggerated secretory response to histamine, the basis of a diagnostic test' (Black)
